Triple meeting 2024 – plenary focus
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.
Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
ESMO 2024 – Regeneron's fianlimab do-over
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ESMO 2024 movers – VEGF bispecifics win, TIGIT loses
After a conference lacking the wow factor, biotech winners and losers emerge.
